Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (354) 354
Publication (35) 35
Book Chapter (3) 3
Book Review (2) 2
Magazine Article (2) 2
Patent (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (195) 195
male (133) 133
female (110) 110
cardiac & cardiovascular systems (101) 101
middle aged (101) 101
adult (85) 85
index medicus (66) 66
aged (62) 62
chagas cardiomyopathy - physiopathology (32) 32
cardiomyopathy (31) 31
echocardiography (28) 28
medicine, general & internal (28) 28
chronic disease (27) 27
heart diseases (27) 27
medicine, research & experimental (27) 27
myocardial infarction (27) 27
risk factors (27) 27
abridged index medicus (26) 26
heart-disease (25) 25
treatment outcome (25) 25
biology (23) 23
chagas' disease (23) 23
mortality (23) 23
medicine (22) 22
cardiology (21) 21
chagas disease (21) 21
disease (21) 21
animals (19) 19
cardiovascular disease (18) 18
prospective studies (18) 18
cardiovascular (17) 17
care and treatment (17) 17
electrocardiography (17) 17
heart failure (17) 17
heart rate (17) 17
time factors (17) 17
double-blind method (16) 16
drug therapy (16) 16
follow-up studies (16) 16
adolescent (15) 15
cardiovascular diseases (15) 15
chagas cardiomyopathy - diagnostic imaging (15) 15
clinical trials (15) 15
analysis (14) 14
cardiovascular diseases - prevention & control (14) 14
heart attacks (14) 14
parasitology (14) 14
stroke (14) 14
chagas cardiomyopathy - complications (13) 13
drug therapy, combination (13) 13
exercise test (13) 13
heart rate - drug effects (13) 13
stroke volume (13) 13
tropical medicine (13) 13
ventricular dysfunction, left - diagnostic imaging (13) 13
diseases of the circulatory system (12) 12
myocardial-infarction (12) 12
parasitic diseases (12) 12
patients (12) 12
prevention (12) 12
prognosis (12) 12
risk (12) 12
trypanocidal agents - therapeutic use (12) 12
blood pressure (11) 11
chagas cardiomyopathy - diagnosis (11) 11
chagas cardiomyopathy - drug therapy (11) 11
heart (11) 11
hemodynamics (11) 11
medicine & public health (11) 11
pathogenesis (11) 11
percutaneous coronary intervention (11) 11
radiology, nuclear medicine & medical imaging (11) 11
atropine - pharmacology (10) 10
cardiovascular diseases - mortality (10) 10
dysfunction (10) 10
exercise (10) 10
imaging / radiology (10) 10
life sciences (10) 10
nuclear medicine (10) 10
parasympathetic nervous system - physiopathology (10) 10
predictive value of tests (10) 10
risk assessment (10) 10
severity of illness index (10) 10
trypanosoma-cruzi infection (10) 10
ventricular dysfunction, left - physiopathology (10) 10
autonomic nervous system - physiopathology (9) 9
benznidazole (9) 9
brazil (9) 9
chagas disease - physiopathology (9) 9
coronary angiography (9) 9
diagnosis (9) 9
infections (9) 9
magnetic resonance imaging (9) 9
myocardial contraction (9) 9
myocardial infarction - drug therapy (9) 9
nitroimidazoles - therapeutic use (9) 9
research (9) 9
research article (9) 9
thallium radioisotopes (9) 9
aged, 80 and over (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents: The OPTIMIZE Randomized Trial
by Feres, Fausto and Costa, Ricardo A and Abizaid, Alexandre and Leon, Martin B and Marin-Neto, J. Antônio and Botelho, Roberto V and King, Spencer B and Negoita, Manuela and Liu, Minglei and de Paula, J. Eduardo T and Mangione, José A and Meireles, George X and Castello, Hélio J and Nicolela, Eduardo L and Perin, Marco A and Devito, Fernando S and Labrunie, André and Salvadori, Décio and Gusmão, Marcos and Staico, Rodolfo and Costa, J. Ribamar and de Castro, Juliana P and Abizaid, Andrea S and Bhatt, Deepak L and OPTIMIZE Trial Investigators
JAMA, ISSN 0098-7484, 12/2013, Volume 310, Issue 23, pp. 2510 - 2522
IMPORTANCE The current recommendation is for at least 12 months of dual antiplatelet therapy after implantation of a drug-eluting stent. However, the optimal... 
DRUG | CLOPIDOGREL THERAPY | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | OPTICAL COHERENCE TOMOGRAPHY | NONCARDIAC SURGERY | IMPLANTATION | TERM CLINICAL-OUTCOMES | DOUBLE-BLIND | FOLLOW-UP | BARE-METAL STENT | Drug-Eluting Stents | Sirolimus - analogs & derivatives | Stroke | Drug Administration Schedule | Humans | Middle Aged | Male | Risk | Hemorrhage | Thrombosis | Ticlopidine - analogs & derivatives | Aspirin - administration & dosage | Sirolimus - administration & dosage | Myocardial Infarction | Coronary Artery Disease - therapy | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Acute Coronary Syndrome - therapy | Female | Aged | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Aggregation | Treatment outcome | Dosage and administration | Research | Blood platelets | Clinical trials | Comparative studies | Drug therapy | Stents | Clinical outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
by Cannon, Christopher P and Blazing, Michael A and Giugliano, Robert P and McCagg, Amy and White, Jennifer A and Theroux, Pierre and Darius, Harald and Lewis, Basil S and Ophuis, Ton Oude and Jukema, J. Wouter and De Ferrari, Gaetano M and Ruzyllo, Witold and De Lucca, Paul and Im, KyungAh and Bohula, Erin A and Reist, Craig and Wiviott, Stephen D and Tershakovec, Andrew M and Musliner, Thomas A and Braunwald, Eugene and Califf, Robert M and IMPROVW-IT Investigators and IMPROVE-IT Investigators
The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At... 
CHOLESTEROL ABSORPTION | CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | CARDIOVASCULAR OUTCOMES | CLINICAL-TRIALS | SIMVASTATIN | PRIMARY PREVENTION | IMPROVE-IT | ATORVASTATIN | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
by Schwartz, Gregory G and Steg, P. Gabriel and Szarek, Michael and Bhatt, Deepak L and Bittner, Vera A and Diaz, Rafael and Edelberg, Jay M and Goodman, Shaun G and Hanotin, Corinne and Harrington, Robert A and Jukema, J. Wouter and Lecorps, Guillaume and Mahaffey, Kenneth W and Moryusef, Angèle and Pordy, Robert and Quintero, Kirby and Roe, Matthew T and Sasiela, William J and Tamby, Jean-François and Tricoci, Pierluigi and White, Harvey D and Zeiher, Andreas M and ODYSSEY OUTCOMES Comm Inv and ODYSSEY OUTCOMES Committees and Investigators
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 22, pp. 2097 - 2107
Among patients who had had an acute coronary syndrome, the risk of death from coronary heart disease, nonfatal myocardial infarction, stroke, or unstable... 
MEDICINE, GENERAL & INTERNAL | MANAGEMENT | MYOCARDIAL-INFARCTION | TASK-FORCE | EFFICACY | SAFETY | LDL | REDUCING LIPIDS | PCSK9 | MONOCLONAL-ANTIBODY | ASSOCIATION | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Acute Coronary Syndrome - complications | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Cardiovascular Diseases - epidemiology | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia - complications | Aged | Acute coronary syndrome | Diagnosis | Myocardial infarction | Fees & charges | Lipoproteins (low density) | Heart attacks | Lipids | Cardiovascular disease | Angina | Apolipoprotein B | Ischemia | Heart diseases | Drug dosages | Statins | Cerebral infarction | Stroke | Subtilisin | Angina pectoris | Patients | Low density lipoprotein | Coronary artery disease | Cholesterol | Kexin | Monoclonal antibodies | Full text | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Pharmaceuticals | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights